Shots:
- The company has reported dosing of the first patient in the US P-III (BiPASS) trial evaluating its PSMA-PET imaging agents, Illuccix and Gozellix, for use in the initial diagnosis of prostate cancer
- BiPASSa P-III study enrolling 250 pts in the US and Australia to support marketing authorization of 68Ga-PSMA-PET in the pre-biopsy setting
- Building on (PRIMARY and PRIMARY2) study data, it will assess whether MRI combined with Illuccix/Gozellix 68Ga-PSMA-11 PET improves diagnostic accuracy and reduces unnecessary prostate biopsies vs standard practice, potentially enhancing patient experience and expanding access to precision imaging
Ref: Telix | Image: Telix | Press Release
Related News: Telix Pharmaceuticals Reports Preliminary P-II (IPAX-Linz) Trial Data of TLX101 to Treat Glioma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
